RenovoRx, Inc. Profile Avatar - Palmy Investing

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath …

Biotechnology
US, Los Altos [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

RenovoRx, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

RenovoRx, Inc. can't present revenue by segment

End of RNXT's Analysis
CIK: 1574094 CUSIP: 75989R107 ISIN: US75989R1077 LEI: - UEI: -
Secondary Listings
RNXT has no secondary listings inside our databases.